NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma

References

• Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23. doi:10.1038/nrc2291.
   PubMed Web of Science ®Google Scholar
• Damm-Welk C, Klapper W, Oschlies I, Gesk S, Rottgers S, Bradtke J, Siebert R, Reiter A, Woessmann W. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol. 2009;146:306–309. doi:10.1111/j.1365-2141.2009.07754.x.
   PubMed Web of Science ®Google Scholar
• Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897–903. doi:10.1200/JCO.2008.18.1487.
   PubMed Web of Science ®Google Scholar
• Alexander S, Kraveka JM, Weitzman S, Lowe E, Smith L, Lynch JC, Chang M, Kinney MC, Perkins SL, Laver J, et al. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children’s oncology group. Pediatr Blood Cancer. 2014;61:2236–2242. doi:10.1002/pbc.25187.
   PubMed Web of Science ®Google Scholar
• Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106:djt378. doi:10.1093/jnci/djt378.
   PubMedGoogle Scholar
• Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709–2717. doi:10.1182/blood-2017-05-780049.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, Kremens B, Lang P, Fuhrer M, Kuhne T, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents–a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133:176–182. doi:10.1111/j.1365-2141.2006.06004.x.
   PubMed Web of Science ®Google Scholar
• Strullu M, Thomas C, Le Deley MC, Chevance A, Kanold J, Bertrand Y, Jubert C, Dalle JH, Paillard C, Baruchel A, et al. Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC. Bone Marrow Transplant. 2015;50:795–801. doi:10.1038/bmt.2015.57.
   PubMed Web of Science ®Google Scholar
• Fukano R, Mori T, Kobayashi R, Mitsui T, Fujita N, Iwasaki F, Suzumiya J, Chin M, Goto H, Takahashi Y, et al. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. Br J Haematol. 2015;168:557–563. doi:10.1111/bjh.13167.
   PubMed Web of Science ®Google Scholar
• Werner MT, Zhao C, Zhang Q, Wasik MA. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood. 2017;129:823–831. doi:10.1182/blood-2016-05-717793.
   PubMed Web of Science ®Google Scholar
• Stadler S, Singh VK, Knorr F, Damm-Welk C, Woessmann W. Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. Cancers (Basel). 2018;10:114. doi:10.3390/cancers10040114.
   Web of Science ®Google Scholar
• Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood. 2010;115:3314–3319. doi:10.1182/blood-2009-11-251892.
   PubMed Web of Science ®Google Scholar
• Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K, Reiter A, Rosolen A, Woessmann W. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27:416–422. doi:10.1038/leu.2012.205.
   PubMed Web of Science ®Google Scholar
• Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood. 2002;99:2100–2106. doi:10.1182/blood.V99.6.2100.
   PubMed Web of Science ®Google Scholar
• Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola M, Gianni AM, Gambacorti-Passerini C. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica. 2006;91:48–55.
   PubMed Web of Science ®Google Scholar
• Ait-Tahar K, Cerundolo V, Banham AH, Hatton C, Blanchard T, Kusec R, Becker M, Smith GL, Pulford K. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer. 2006;118:688–695. doi:10.1002/ijc.21410.
   PubMed Web of Science ®Google Scholar
• Ait-Tahar K, Barnardo MC, Pulford K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res. 2007;67:1898–1901. doi:10.1158/0008-5472.CAN-06-4427.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Martinengo C, Mastini C, Ambrogio C, D’Escamard V, Forni G, Inghirami G. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008;14:676–680. doi:10.1038/nm1769.
   PubMed Web of Science ®Google Scholar
• Singh VK, Werner S, Hackstein H, Lennerz V, Reiter A, Wolfel T, Damm-Welk C, Woessmann W. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma. Clin Exp Immunol. 2016;186:96–105. doi:10.1111/cei.12842.
   PubMed Web of Science ®Google Scholar
• Melief CJ. van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351–360. doi:10.1038/nrc2373.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Nishimura Y. Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells. Oncoimmunology. 2013;2:e25801. doi:10.4161/onci.25801.
   PubMed Web of Science ®Google Scholar
• Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89:1394–1404.
   PubMed Web of Science ®Google Scholar
• Nair S, Boczkowski D. RNA-transfected dendritic cells. Expert Rev Vaccines. 2002;1:507–513. doi:10.1586/14760584.1.4.507.
   PubMedGoogle Scholar
• Weiner DB. RNA-based vaccination: sending a strong message. Mol Ther. 2013;21:506–508. doi:10.1038/mt.2013.26.
   PubMed Web of Science ®Google Scholar
• McNamara MA, Nair SK, Holl EK. RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res. 2015;2015:794528. doi:10.1155/2015/794528.
   PubMed Web of Science ®Google Scholar
• Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16:364–369. doi:10.1038/nbt0498-364.
   PubMed Web of Science ®Google Scholar
• Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol. 2000;164:5508–5514. doi:10.4049/jimmunol.164.10.5508.
   PubMed Web of Science ®Google Scholar
• Morandi F, Chiesa S, Bocca P, Millo E, Salis A, Solari M, Pistoia V, Prigione I. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia. 2006;8:833–842. doi:10.1593/neo.06415.
   PubMed Web of Science ®Google Scholar
• Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jager E, Tiercy JM, van Den Broek M, Pascolo S, Knuth A, Zippelius A. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother. 2009;58:325–338. doi:10.1007/s00262-008-0556-8.
   PubMed Web of Science ®Google Scholar
• Gholamin M, Moaven O, Farshchian M, Mahmoudi M, Sankian M, Memar B, Forghani MN, Malekzadeh R, Rajabi-Mashhadi MT, Abbaszadegan MR. Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design. BMC Cancer. 2010;10:261. doi:10.1186/1471-2407-10-261.
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63:2127–2133.
   PubMed Web of Science ®Google Scholar
• Muller MR, Tsakou G, Grunebach F, Schmidt SM, Brossart P. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood. 2004;103:1763–1769. doi:10.1182/blood-2003-06-2097.
   PubMed Web of Science ®Google Scholar
• Kyte JA, Aamdal S, Dueland S, Saeboe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology. 2016;5:e1232237. doi:10.1080/2162402X.2016.1232237.
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798–3807. doi:10.4049/jimmunol.174.6.3798.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010;107:13824–13829. doi:10.1073/pnas.1008051107.
   PubMed Web of Science ®Google Scholar
• Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, van der Bruggen P, Coulie PG, Neyns B, Thielemans K, et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther. 2012;20:1063–1074. doi:10.1038/mt.2012.11.
   PubMed Web of Science ®Google Scholar
• Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383. doi:10.1155/2013/976383.
   PubMed Web of Science ®Google Scholar
• Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 2000;12:107–117. doi:10.1016/S1074-7613(00)80163-6.
   PubMed Web of Science ®Google Scholar
• Schultz ES, Chapiro J, Lurquin C, Claverol S, Burlet-Schiltz O, Warnier G, Russo V, Morel S, Levy F, Boon T, et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med. 2002;195:391–399. doi:10.1084/jem.20011974.
   PubMed Web of Science ®Google Scholar
• Anderson KS, Zeng W, Sasada T, Choi J, Riemer AB, Su M, Drakoulakos D, Kang YJ, Brusic V, Wu C, et al. Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother. 2011;60:857–867. doi:10.1007/s00262-011-0995-5.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994;24:3038–3043. doi:10.1002/eji.1830241218.
   PubMed Web of Science ®Google Scholar
• Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P, Cerundolo V, Levy F. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med. 1999;189:895–906. doi:10.1084/jem.189.6.895.
   PubMed Web of Science ®Google Scholar
• Chapatte L, Ayyoub M, Morel S, Peitrequin AL, Levy N, Servis C, Van Den Eynde BJ, Valmori D, Levy F. Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. Cancer Res. 2006;66:5461–5468. doi:10.1158/0008-5472.CAN-05-4310.
   PubMed Web of Science ®Google Scholar
• Rock KL, Rothstein L, Benacerraf B. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc Natl Acad Sci U S A. 1992;89:8918–8922. doi:10.1073/pnas.89.19.8918.
   PubMed Web of Science ®Google Scholar
• Pm D, Jw Y, Porgador A, Rn G, Jr B. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc Natl Acad Sci U S A. 1997;94:8064–8069. doi:10.1073/pnas.94.15.8064.
   PubMed Web of Science ®Google Scholar
• Luft T, Rizkalla M, Tai TY, Chen Q, MacFarlan RI, Davis ID, Maraskovsky E, Cebon J. Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation. J Immunol. 2001;167:2529–2537. doi:10.4049/jimmunol.167.5.2529.
   PubMed Web of Science ®Google Scholar
• Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Jw D, Ar V, Ar W, Oostendorp J, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178–187. doi:10.1158/1078-0432.CCR-07-1880.
   PubMed Web of Science ®Google Scholar
• Leffers N, Vermeij R, Bn H, Ur S, Wolf R, Ie H, Ag VDZ, Kj M, Sh VDB, Daemen T, et al. Long-term clinical and immunological effects of p53-SLP(R) vaccine in patients with ovarian cancer. Int J Cancer. 2012;130:105–112. doi:10.1002/ijc.25980.
   PubMed Web of Science ®Google Scholar
• Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, Silva AL, Jiskoot W, van Hall T, van Veelen PA, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol. 2013;43:2554–2565. doi:10.1002/eji.201343324.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, Haig N, Di Gleria K, Yu Z, Xu XN, et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. J Biol Chem. 2009;284:9184–9191. doi:10.1074/jbc.M809456200.
   PubMed Web of Science ®Google Scholar
• Jenkins MK, Moon JJ. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol. 2012;188:4135–4140. doi:10.4049/jimmunol.1102661.
   PubMed Web of Science ®Google Scholar
• Yu W, Jiang N, Ebert PJ, Kidd BA, Muller S, Lund PJ, Juang J, Adachi K, Tse T, Birnbaum ME, et al. Clonal deletion prunes but does not eliminate self-specific alphabeta CD8(+) T Lymphocytes. Immunity. 2015;42:929–941. doi:10.1016/j.immuni.2015.05.001.
   PubMed Web of Science ®Google Scholar
• Knorr F, Weber S, Singh VK, Pulford K, Reiter A, Woessmann W, Damm-Welk C. Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma. Clin Immunol. 2018;195:77–81. doi:10.1016/j.clim.2018.07.008.
   PubMed Web of Science ®Google Scholar
• Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, et al. Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget. 2017;8:92265–92274. doi:10.18632/oncotarget.21182.
   PubMedGoogle Scholar
• Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–1284. doi:10.1126/science.8122112.
   PubMed Web of Science ®Google Scholar
• Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol. 2005;7:823–830. doi:10.1038/ncb1282.
   PubMed Web of Science ®Google Scholar
• Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003;170:4069–4076. doi:10.4049/jimmunol.170.8.4069.
   PubMed Web of Science ®Google Scholar
• Desombere I, Meuleman P, Rigole H, Willems A, Irsch J, Leroux-Roels G. The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level. J Immunol Methods. 2004;286:167–185. doi:10.1016/j.jim.2004.01.001.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children’s oncology group study. J Clin Oncol. 2017;35:3215–3221. doi:10.1200/JCO.2017.73.4830.
   PubMed Web of Science ®Google Scholar